Cancer genes and the pathways they control

Nature Medicine

Volumn 10, Issue 8, 2004, Pages 789-799

  Vogelstein, Bert ^a   Kinzler, Kenneth W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AXIN; FAS LIGAND; GENE PRODUCT; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; SMAD PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UVOMORULIN;

ANGIOGENESIS; APOPTOSIS; CANCER GENETICS; CELL PROLIFERATION; DOMINANT INHERITANCE; GENE MUTATION; GENE TRANSLOCATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECESSIVE INHERITANCE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; X CHROMOSOMAL INHERITANCE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOMATOUS POLYPOSIS COLI PROTEIN; APOPTOSIS; DNA REPAIR; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4043181214     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1087     Document Type: Review

References (118)

1. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
2. Wan, P.T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
3. Santarosa, M. & Ashworth, A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim. Biophys. Acta 1654, 105-122 (2004).
4. Knudson, A.G. Cancer genetics. Am. J. Med. Genet. 111, 96-102 (2002).
5. Friedberg, E.C. DNA damage and repair. Nature 421, 436-440 (2003).
6. Nowell, P.C. Tumor progression: a brief historical perspective. Semin. Cancer Biol. 12, 261-266 (2002).
7. Maley, C.C. et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. 64, 3414-3427 (2004).
8. Van Dyke, T. & Jacks, T. Cancer modeling in the modern era: progress and challenges. Cell 108, 135-144 (2002).
9. Horvitz, H.R. Worms, life, and death. Chembiochem 4, 697-711 (2003).
10. Sherr, C.J. Cancer cell cycles revisited. Cancer Res. 60, 3689-3695 (2000).
11. Ortega, S., Malumbres, M. & Barbacid, M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 1602, 73-87 (2002).
12. Classon, M. & Harlow, E. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2, 910-917 (2002).
13. Ichimura, K. et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 60, 417-424 (2000).
14. Vogelstein, B., Lane, D. & Levine, A.J. Surfing the p53 network. Nature 408, 307-310 (2000).
15. Oren, M. Decision making by p53: life, death and cancer. Cell Death Differ. 10, 431-442 (2003).
16. Prives, C. & Hall, P.A. The p53 pathway. J. Pathol. 187, 112-126 (1999).
17. Klein, G. Perspectives in studies of human tumor viruses. Front. Biosci. 7, d268-d274 (2002).
18. Munger, K. & Howley, P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 89, 213-228 (2002).
19. zur Hausen, H. Oncogenic DNA viruses. Oncogene 20, 7820-7823 (2001).
20. Hunter, T. Signaling-2000 and beyond. Cell 100, 113-127 (2000).
21. Komarova, N.L., Sengupta, A. & Nowak, M.A. Mutation-selection networks of cancer initiation: tumor suppressor genes and chromosomal instability. J. Theor. Biol. 223, 433-450 (2003).
22. Rowley, J.D. The critical role of chromosome translocations in human leukemias. Annu. Rev. Genet. 32, 495-519 (1998).
23. Mitelman, F. Recurrent chromosome aberrations in cancer. Mutat. Res. 462, 247-253 (2000).
24. Verheul, H.M., Voest, E.E. & Schlingemann, P.O. Are tumours angiogenesis-dependent? J. Pathol. 202, 5-13 (2004).
25. Tlsty, T.D. & Hein, P.W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11, 54-59 (2001).
26. Fata, J.E., Werb, Z. & Bissell, M.J. Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res. 6, 1-11 (2004).
27. Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2, 727-739 (2002).
28. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18 (2002).
29. Ferrara, N., Hillan, K.J., Gerber, H.P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004).
30. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W.G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002).
31. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003).
32. Strausberg, R.L., Simpson, A.J. & Wooster, R. Sequence-based cancer genomics: progress, lessons and opportunities. Nat. Rev. Genet. 4, 409-418 (2003).
33. Loeb, L.A., Loeb, K.R. & Anderson, J.P. Multiple mutations and cancer. Proc. Natl. Acad. Sci. USA 100, 776-781 (2003).
34. Rajagopalan, H., Nowak, M.A., Vogelstein, B. & Lengauer, C. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer 3, 695-701 (2003).
35. Sieber, O.M., Heinimann, K. & Tomlinson, I.P. Genomic instability - the engine of tumorigenesis? Nat. Rev. Cancer 3, 701-708 (2003).
36. Wang, T.L. et al. Prevalence of somatic alterations in the colorectal cancer cell genome. Proc. Natl. Acad. Sci. USA 99, 3076-3080 (2002).
37. Lengauer, C., Kinzler, K.W. & Vogelstein, B. Genetic instabilities in human cancers. Nature 396, 643-649 (1998).
38. Duesberg, P. & Li, R. Multistep carcinogenesis: a chain reaction of aneuploidizations. Cell Cycle 2, 202-210 (2003).
39. Albertson, D.G. & Pinkel, D. Genomic microarrays in human genetic disease and cancer. Hum. Mol. Genet. 12 (spec. no. 2), R145-R152 (2003).
40. Shiloh, Y. & Kastan, M.B. ATM: genome stability, neuronal development, and cancer cross paths. Adv. Cancer Res. 83, 209-254 (2001).
41. Scully, R. & Livingston, D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408, 429-432 (2000).
42. Maser, R.S. & DePinho, R.A. Connecting chromosomes, crisis, and cancer. Science 297, 565-569 (2002).
43. Pihan, G. & Doxsey, S.J. Mutations and aneuploidy: co-conspirators in cancer? Cancer Cell 4, 89-94 (2003).
44. Rajagopalan, H. et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 428, 77-81 (2004).
45. Shay, J.W. & Roninson, I.B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23, 2919-2933 (2004).
46. Chambers, A.F., Groom, A.C. & MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).
47. Fidler, I.J. Critical determinants of metastasis. Semin. Cancer Biol. 12, 89-96 (2002).
48. Hunter, K.W. Host genetics and tumour metastasis. Br. J. Cancer 90, 752-755 (2004).
49. Hruban, R.H., Goggins, M., Parsons, J. & Kern, S.E. Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969-2972 (2000).
50. Aguirre, A.J. et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112-3126 (2003).
51. Jen, J. et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54, 5523-5526 (1994).
52. Pretlow, T.P. Aberrant crypt foci and K-ras mutations: earliest recognized players or innocent bystanders in colon carcinogenesis? Gastroenterology 108, 600-603 (1995).
53. Sieben, N.L. et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 202, 336-340 (2004).
54. Kinzler, K.W. & Vogelstein, B. Colorectal Tumors. in The Genetic Basis of Human Cancer (eds. Vogelstein, B. & Kinzler, K.W.) 565-587 (McGraw-Hill, New York, 1998).
55. Barbacid, M. ras genes. Annu. Rev. Biochem. 56, 779-827 (1987).
56. Bos, J.L. ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689 (1989).
57. Zhang, Z. et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 29, 25-33 (2001).
58. Diaz, R. et al. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res. 62, 4514-4518 (2002).
59. Bronner-Fraser, M. Development. Making sense of the sensory lineage. Science 303, 966-968 (2004).
60. Jiricny, J. Eukaryotic mismatch repair: an update. Mutat. Res. 409, 107-121 (1998).
61. Fishel, R. & Wilson, T. MutS homologs in mammalian cells. Curr. Opin. Genet. Dev. 7, 105-113 (1997).
62. Lynch, H.T. & de la Chapelle, A. Hereditary colorectal cancer. N. Engl. J. Med. 348, 919-932 (2003).
63. Yamamoto, H., Imai, K. & Perucho, M. Gastrointestinal cancer of the microsatellite mutator phenotype pathway. J. Gastroenterol. 37, 153-163 (2002).
64. Honchel, R., Halling, K.C. & Thibodeau, S.N. Genomic instability in neoplasia. Semin. Cell Biol. 6, 45-52 (1995).
65. Brown, P.O. & Botstein, D. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21, 33-37 (1999).
66. Polyak, K. & Riggins, G.J. Gene discovery using the serial analysis of gene expression technique: implications for cancer research. J. Clin. Oncol. 19, 2948-2958 (2001).
67. Jones, P.A. & Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415-428 (2002).
68. Feinberg, A.P. & Tycko, B. The history of cancer epigenetics. Nat. Rev. Cancer 4, 143-153 (2004).
69. Collins, F.S., Green, E.D., Guttmacher, A.E. & Guyer, M.S. A vision for the future of genomics research. Nature 422, 835-847 (2003).
70. Schadt, E.E., Monks, S.A. & Friend, S.H. A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets. Biochem. Soc. Trans. 31, 437-443 (2003).
71. Paddison, P.J. et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 428, 427-431 (2004).
72. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
73. Rosenblatt, K.P. et al. Serum proteomics in cancer diagnosis and management. Annu. Rev. Med. 55, 97-112 (2004).
74. Luo, J., Isaacs, W.B., Trent, J.M. & Duggan, D.J. Looking beyond morphology: cancer gene expression profiling using DNA microarrays. Cancer Invest. 21, 937-949 (2003).
75. Ma, X.J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616 (2004).
76. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
77. Masayesva, B.G. et al. Gene expression alterations over large chromosomal regions in cancers include multiple genes unrelated to malignant progression. Proc. Natl. Acad. Sci. USA 101, 8715-8720 (2004).
78. Stewart, S.A. & Weinberg, R.A. Senescence: does it all happen at the ends? Oncogene 21, 627-630 (2002).
79. Feldser, D.M., Hackett, J.A. & Greider, C.W. Telomere dysfunction and the initiation of genome instability. Nat. Rev. Cancer 3, 623-627 (2003).
80. Chan, S.R. & Blackburn, E.H. Telomeres and telomerase. Phil. Trans. R. Soc. Lond. B 359, 109-121 (2004).
81. Cech, T.R. Beginning to understand the end of the chromosome. Cell 116, 273-279 (2004).
82. Miklos, G.L. & Maleszka, R. Microarray reality checks in the context of a complex disease. Nat. Biotechnol. 22, 615-621 (2004).
83. Hope, K.J., Jin, L. & Dick, J.E. Human acute myeloid leukemia stem cells. Arch. Med. Res. 34, 507-514 (2003).
84. Berking, C. & Herlyn, M. Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histol. Histopathol. 16, 669-674 (2001).
85. Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966-4971 (2004).
86. Frei, E.I. & Eder, J.P. Principles of dose, schedule, and combination Therapy. in Cancer Medicine (eds. Kufe, D.W. et al.) 669-677 (B.C. Decker, Inc., Hamilton, Ontario, 2003).
87. Pegram, M.D., Konecny, G. & Slamon, D.J. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat. Res. 103, 57-75 (2000).
88. Druker, B.J. et al. Chronic myelogenous leukemia. in Hematology 2001 (American Society of Hematology Education Program) 87-112 (American Society of Hematology, 2001).
89. Mechtersheimer, G. et al. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch. 444, 108-118 (2004).
90. Langer, C.J. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int. J. Radiat. Oncol. Biol. Phys. 58, 991-1002 (2004).
91. Duensing, A., Heinrich, M.C., Fletcher, C.D. & Fletcher, J.A. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest. 22, 106-116 (2004).
92. Paez, J.G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
93. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
94. Schmitt, C.A. & Lowe, S.W. Apoptosis and therapy. J. Pathol. 187, 127-137 (1999).
95. Danial, N.N. & Korsmeyer, S.J. Cell death: critical control points. Cell 116, 205-219 (2004).
96. Brown, J.M. & Wouters, B.G. Apoptosis: mediator or mode of cell killing by anticancer agents? Drug Resist. Updat. 4, 135-136 (2001).
97. Weinstein, I.B. et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin. Cancer Res. 3, 2696-2702 (1997).
98. Nygren, P. & Larsson, R. Overview of the clinical efficacy of investigational anticancer drugs. J. Intern. Med. 253, 46-75 (2003).
99. Shih, L.Y. et al. Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples. Clin. Cancer Res. 10, 1326-1332 (2004).
100. Kinzler, K.W. & Vogelstein, B. Lessons from hereditary colon cancer. Cell 87, 159-170 (1996).
101. Weissleder, R. & Ntziachristos, V. Shedding light onto live molecular targets. Nat. Med. 9, 123-128 (2003).
102. Sidransky, D. Emerging molecular markers of cancer. Nat. Rev. Cancer 2, 210-219 (2002).
103. Gschwind, A., Fischer, O.M. & Ullrich, A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4, 361-370 (2004).
104. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003).
105. Malumbres, M. & Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1, 222-231 (2001).
106. Giles, R.H., van Es, J.H. & Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653, 1-24 (2003).
107. Cantley, L.C. The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002).
108. Shi, Y. & Massague, J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
109. Ruiz i Altaba, A., Stecca, B. & Sanchez, P. Hedgehog-Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer. Cancer Lett. 204, 145-157 (2004).
110. Adams, J.M. Ways of dying: multiple pathways to apoptosis. Genes Dev. 17, 2481-2495 (2003).
111. Blagosklonny, M.V. & Pardee, A.B. The restriction point of the cell cycle. Cell Cycle 1, 103-110 (2002).
112. Plas, D.R. & Thompson, C.B. Cell metabolism in the regulation of programmed cell death. Trends Endocrinol. Metab. 13, 75-78 (2002).
113. Green, D.R. & Evan, G.I. A matter of life and death. Cancer Cell 1, 19-30 (2002).
114. Eng, C., Kiuru, M., Fernandez, M.J. & Aaltonen, L.A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat. Rev. Cancer 3, 193-202 (2003).
115. Lum, L. & Beachy, P.A. The Hedgehog response network: sensors, switches, and routers. Science 304, 1755-1759 (2004).
116. Brivanlou, A.H. & Darnell, J.E. Jr. Signal transduction and the control of gene expression. Science 295, 813-818 (2002).
117. Vogelstein, B. & Kinzler, K.W. The Genetic Basis of Human Cancer (McGraw-Hill, Toronto, 2002).
118. Cameron, E.R. & Neil, J.C. The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene 23, 4308-4314 (2004).